Portal hypertension

This study looks at a new way to do liver transplants for people with severe portal hypertension. Instead of using a full-sized liver, doctors will use a smaller piece (small-for-size graft) in an auxiliary transplant, leaving part of the original liver in place. The goal is to s…

This study tests whether beta-blockers, a type of blood pressure medicine, can reduce the risk of bleeding from small varices in people with cirrhosis and portal hypertension. About 763 adults with small varices will receive either beta-blockers or a placebo for up to 3 years. Th…

This study tests a hospital program to avoid giving NSAIDs or metamizole to people with advanced chronic liver disease who need major surgery. These painkillers are risky for them because they can cause kidney damage, fluid buildup, or bleeding. The program will track how often t…

This trial is testing a medical device that has not been approved or cleared by the U.S. FDA. The study is small and early-stage, focused on understanding how the device works and whether it is safe. No results are available yet, and the device is not ready for widespread use.

This study follows about 400 adults with liver cirrhosis admitted to internal medicine wards across Italy. Researchers will track how doctors manage hepatic encephalopathy—a brain complication of liver disease—during hospitalization and after discharge. The goal is to identify pr…

This observational study looks at the financial and social challenges faced by informal caregivers of people with cirrhosis. Researchers will measure out-of-pocket costs, lost work time, and financial distress using surveys. The goal is to understand how these burdens affect care…

This study follows 852 adults with liver cirrhosis who are scheduled for a TIPS procedure, a shunt placed in the liver to relieve dangerous high blood pressure. Researchers will collect information from standard medical care over 5 years to learn how to best use TIPS and reduce c…

This observational study follows 11 patients with chronic hepatitis B and delta coinfection and liver cirrhosis who are already receiving the antiviral drug Bulevirtide. Researchers want to see if suppressing the virus reduces portal hypertension—a dangerous buildup of pressure i…